Clinical trials: Allogeneic Stem Cell Transplant
- Condition Allogeneic Stem Cell Transplant
- Age group Children (under 18)
- Accepts healthy volunteers yes
Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
This phase I trial investigates the side effects and effectiveness of chemotherapy followed by a donor (allogeneic) stem cell transplant when given to patients with high grade brain cancer.
- Conditions
- Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Germ Cell Tumor, Choroid Plexus Carcinoma
- Trial name
- NCT04521946
- Testing
- Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Graft vs Host Disease
GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease
Acute graft versus host disease (GVHD) remains one of the most significant and potentially lethal complications of allogeneic bone marrow transplantation.
- Trial name
- NCT00228839
- Testing
- Infliximab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
CMV Infection, Hematopoietic Stem Cell Transplantation
Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT05656599
- Testing
- Letermovir
- Where
- 2 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Hematological Malignancies
Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings
The present project aims at comparing two nonmyeloablative regimens currently used in 2 major HCT centers in the US for patients with HLA-matched related or unrelated donor: the one from the Seattle group consisting of 2 Gy TBI…
- Trial name
- NCT00603954
- Testing
- Conditioning regimen: TBI + Fludarabine, Conditioning regimen:TLI (8 Gy) + ATG
- Where
- 11 sites in Belgium, Netherlands
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Liege
Graft Failure, Sickle Cell Disease
Allo HSCT for High Risk Hemoglobinopathies
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation…
- Conditions
- Graft Failure, Sickle Cell Disease, Hemoglobinopathies
- Trial name
- NCT06872333
- Testing
- Alemtuzumab, Total Body Irradiation, Cell Infusion
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma, Leukemia
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
RATIONALE: Following stem cell transplantation, a major risk is graft-versus-host disease (GVHD). This occurs when donor immune cells that have been infused recognise the host's cells as 'foreign' and attack these cells.
- Conditions
- Lymphoma, Leukemia, Myeloma, Myelodysplastic Syndromes
- Trial name
- ToTem (NCT03836690)
- Testing
- CD62L- Tem
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University College, London
Hematopoietic Stem Cell Transplant, Hematologic Malignancy
Influenza Vaccine Post Allogeneic Transplant
Study Design: This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine…
- Trial name
- NCT01215981
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Myelocytic, Acute
Infection and Tumour Antigen Cellular Therapy
This study is to test a new therapy for patients with acute myeloid leukaemia who are undergoing blood stem cell transplant. In this study, the investigators will take a small number of your immune cells whose normal function is…
- Trial name
- INTACT-WT1 (NCT02895412)
- Testing
- Donor-derived WT1-CTL and P-CTL
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Sydney
Acute Biphenotypic Leukemia, Acute Leukemia
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant.
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
- Trial name
- NCT03779854
- Testing
- Total-Body Irradiation, Thiotepa, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
AML, ALL
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Allogeneic stem cell transplantation may provide long-term remissions for some patients with hematological malignancies. However, allogeneic transplantation is associated with a significant risk of potentially life threatening…
- Conditions
- AML, ALL, CLL, Myelodysplastic Syndrome
- Trial name
- NCT00533923
- Testing
- Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation
HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR
Human cytomegalovirus (HCMV) infection is one of the most common and serious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Virus Reactivation, Graft vs Host Disease
- Trial name
- HSCT-HCMV01 (NCT07210242)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Ting YANG
Hematological Malignancies
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot…
- Trial name
- NCT00504803
- Testing
- Mesenchymal stem cell infusion
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Liege
Allogeneic Stem Cell Transplantation
Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH
The allogeneic hematopoietic stem cell marrow is the only curative treatment for many hematologic malignancies. However, many patients relapse in these situations to be therapeutic possibilities scarce and mixed.
- Trial name
- NCT01212796
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
This phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT02220985
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Graft vs Host Disease
Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease
Mesenchymal stem cells (MSC) have been shown to have immunosuppressive properties. Following a bone marrow/peripheral blood stem cell transplant, a proportion of patients develop a condition called 'graft versus host disease'…
- Trial name
- NCT00314483
- Testing
- Mesenchymal Stem Cell Infusion
- Where
- India
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Christian Medical College, Vellore, India
Antibiotic Resistant Strain
Fecal Microbiome Transplantation (FMT) in Pediatric Patients Colonized With Antibiotic-resistant Pathogens Before Hematopoietic Stem Cell Transplantation (HSCT)
a clinical trial designed to prospectively assess the safety and effectiveness of fecal microbiota transplantation (FMT) prior to allogeneic hematopoietic stem-cell translation (HSCT) in patients contaminated with…
- Trial name
- FMT-HSCT (NCT04593368)
- Testing
- FMT
- Where
- 3 sites in Russia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Blood And Marrow Transplantation
Plerixafor for Stem Cell Mobilization in Normal Donors
The goal of this clinical research study is to learn if treating stem cell donors with filgrastim (G-CSF) and plerixafor (Mozobil®) can cause them to produce a higher number of blood stem cells than filgrastim by itself.
- Trial name
- NCT01818284
- Testing
- Filgrastim, Plerixafor, Apheresis Procedure
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Cytomegalovirus Infections
Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants
The purpose of this study is to test the safety of a transfusion of specialized white cells from your transplant donor's blood, called T-cells, that have been grown and immunized against the CMV virus in the test tube.
- Trial name
- NCT00674648
- Testing
- CMV-Peptide-Specific T cells
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Leukemia
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Background: Patients with cancers of the blood and immune system often benefit from transplants of stem cells from a genetically well-matched sibling.
- Conditions
- Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma
- Trial name
- NCT00074490
- Testing
- Rituximab, Fludarabine, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 442 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)